Valence 로고
인기
로그인
Loading data for CATX — first visit, this takes a few seconds.

관심목록에 추가

Perspective Therapeutics ...

NYSE American: CATX · 실시간 가격 · USD
3.11
-0.07 (-2.20%)
종가 기준: Aug 28, 2026, 3:59 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

Perspective Therapeutics Inc.(CATX) 주가, 분석 및 데이터

-2.20%
매수호가3.05
시가총액355.01M
매출 (ttm)409K
순이익 (ttm)-116.63M
1.80
-1.3
n/a
-3.05
P/B (ttm)1.10
P/S (ttm)868.00
실적 발표일Nov 9, 2026
매도호가3.24
거래량913,084
평균 거래량 (20일)1,654,126
시가3.16
전일 종가3.18
일중 범위3.08 - 3.17
52주 범위1.96 - 6.16
애널리스트n/a
목표주가n/a
배당n/a
배당락일n/a

CATX 소개

Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted r...

[더 보기]
산업 Medical Devices
섹터 Healthcare
IPO 일자 Nov 10, 2005
직원 수 163
상장 거래소 NYSE American
티커 CATX
웹사이트 https://www.perspectivetherapeutics.com
전체 기업 정보

재무 실적

2025년 Perspective Therapeutics의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -103.12M로, 30.07% 증가했습니다.

재무제표

어닝 서프라이즈

Perspective Therapeutics가 Aug 10, 2026에 분기 실적을 발표했습니다:
  • 매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.
  • EPS -0.22 예상치 상회 0.05, 및 26.67% 전년 대비 성장.

다음 실적 발표

Perspective Therapeutics Inc.의 실적 발표 예정일은 Nov 9, 2026, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드
news image

2주 전 · MT Newswires

Perspective Therapeutics's NET Program Data May Allow Phase 3 Trial Start, Value Inflection, RBC Says

Perspective Therapeutics' (CATX) NET program to potentially treat neuroendocrine tumors may be advan

news image

3주 전 · Zacks

Profound Medical (PROF) Q2 Earnings Surpass Estimates

Profound Medical (PROF) delivered earnings and revenue surprises of +218.18% and -55.66%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

news image

3주 전 · Zacks

Are Medical Stocks Lagging Perspective Therapeutics, Inc. (CATX) This Year?

Here is how Perspective Therapeutics (CATX) and Bristol Myers Squibb (BMY) have performed compared to their sector so far this year.

news image

3주 전 · Zacks

4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

Medical sector earnings are off to a strong start, and four biotech companies are positioned to potentially beat estimates in upcoming quarterly results.

news image

1개월 전 · Zacks

Perspective Therapeutics (CATX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for Perspective Therapeutics (CATX), indicating that the stock has found support. This, combined with an upward trend in earnings...

2 페이지 중 1